36 research outputs found
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
Supplementary Figure S2: HPV16-specific T cell responses at different dose levels and time points.</p
Figure S13 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S13. Frequency and activation of circulating myeloid cells during Reo preexposure.</p
Figure S8 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S8. Neutralization capacity of plasma used for the transfer to NSG mice.</p
Figure S10 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S10. Preexposure affects the specificity of Reo-specific CD8+ T cells.</p
Figure S9 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S9. Intratumoral T-cell influx after Reo treatment in ÎĽMT or C57BL/6J mice.</p
Figure S7 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S7. Reo-specific neutralizing antibodies are present 5 days after intratumoral Reo administration.</p
Figure S12 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S12. Influx of immune cells after intratumoral Reo or VSV treatment of KPC3 tumors in Reo-preexposed or VSV-preexposed mice.</p
Figure S6 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S6. B-cell depletion during preexposure does not completely abrogate the presence of Reo-specific neutralizing antibodies.</p
Figure S1 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S1. Bodyweight during preexposure and clodronate liposome treatment.</p
Figure S11 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Figure S11. Induction of circulating VSV-specific NAbs and CD8+ T cells by VSV preexposure.</p